Los CFD son instrumentos complejos y conllevan un alto riesgo de perder dinero rápidamente debido al apalancamiento.El 82.78 % de las cuentas de los inversores minoristas pierde dinero al operar con CFD con este proveedor. Debes plantearte si entiendes cómo funcionan los CFD y si puedes permitirte asumir el elevado riesgo de perder tu dinero.
AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company''s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive Soft Tissue Membrane, a processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues in the surgical bed. In addition, the company offers AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. It provides its products to hospitals, surgery centers, and military hospitals plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons in the United States, Canada, Germany, the United Kingdom and other European countries, South Korea, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.
Warren Buffett acaba de anunciar que dejará su cargo como CEO de Berkshire Hathaway, y le dejará a su sucesor una enorme suma de dinero. Desde 2024, Buffett ha vendido una gran cantidad de acciones, duplicando con creces la posición de efectivo de Berkshire: de $167 mil millones a $348 mil millones.
14:06, 2 julio 2025
Lee nuestras reseñas para conocernos mejor
Lee las opiniones de nuestros clientes, sea cual sea su nivel de experiencia.
Estas son nuestras reseñas de 4 y 5 estrellas. Los datos específicos del usuario se han anonimizado intencionadamente para salvaguardar su privacidad de conformidad con los requisitos del RGPD